| Literature DB >> 34001525 |
Humam Kadara1, Linh M Tran2, Bin Liu2, Anil Vachani3, Shuo Li4, Ansam Sinjab1, Xianghong J Zhou4, Steven M Dubinett2,4,5,6,7, Kostyantyn Krysan2,7.
Abstract
Cancer interception refers to actively blocking the cancer development process by preventing progression of premalignancy to invasive disease. The rate-limiting steps for effective lung cancer interception are the incomplete understanding of the earliest molecular events associated with lung carcinogenesis, the lack of preclinical models of pulmonary premalignancy, and the challenge of developing highly sensitive and specific methods for early detection. Recent advances in cancer interception are facilitated by developments in next-generation sequencing, computational methodologies, as well as the renewed emphasis in precision medicine and immuno-oncology. This review summarizes the current state of knowledge in the areas of molecular abnormalities in lung cancer continuum, preclinical human models of lung cancer pathogenesis, and the advances in early lung cancer diagnostics.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34001525 PMCID: PMC8415293 DOI: 10.1101/cshperspect.a037994
Source DB: PubMed Journal: Cold Spring Harb Perspect Med ISSN: 2157-1422 Impact factor: 6.915